SE0401762D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
SE0401762D0
SE0401762D0 SE0401762A SE0401762A SE0401762D0 SE 0401762 D0 SE0401762 D0 SE 0401762D0 SE 0401762 A SE0401762 A SE 0401762A SE 0401762 A SE0401762 A SE 0401762A SE 0401762 D0 SE0401762 D0 SE 0401762D0
Authority
SE
Sweden
Prior art keywords
novel compounds
pharmaceutical compositions
therapy
preparing
processes
Prior art date
Application number
SE0401762A
Other languages
English (en)
Swedish (sv)
Inventor
Balint Gabos
Lena Ripa
Kristina Stenvall
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0401762A priority Critical patent/SE0401762D0/xx
Publication of SE0401762D0 publication Critical patent/SE0401762D0/xx
Priority to UAA200613009A priority patent/UA86977C2/ru
Priority to SA05260192A priority patent/SA05260192B1/ar
Priority to TW094121763A priority patent/TWI353985B/zh
Priority to MYPI20053029A priority patent/MY145613A/en
Priority to NZ552101A priority patent/NZ552101A/en
Priority to MXPA06014661A priority patent/MXPA06014661A/es
Priority to DE602005017636T priority patent/DE602005017636D1/de
Priority to EP05756403A priority patent/EP1778673B1/en
Priority to CNB2005800228017A priority patent/CN100543024C/zh
Priority to RU2007101236/04A priority patent/RU2386629C2/ru
Priority to DK05756403.1T priority patent/DK1778673T3/da
Priority to AT05756403T priority patent/ATE448219T1/de
Priority to PL05756403T priority patent/PL1778673T3/pl
Priority to ES05756403T priority patent/ES2335424T3/es
Priority to HR20100020T priority patent/HRP20100020T1/hr
Priority to BRPI0512974-5A priority patent/BRPI0512974A/pt
Priority to CA2569716A priority patent/CA2569716C/en
Priority to JP2007520267A priority patent/JP4390833B2/ja
Priority to PCT/SE2005/001092 priority patent/WO2006004532A1/en
Priority to PT05756403T priority patent/PT1778673E/pt
Priority to AU2005260142A priority patent/AU2005260142B2/en
Priority to SI200530892T priority patent/SI1778673T1/sl
Priority to HK07111163.1A priority patent/HK1102814B/en
Priority to KR1020077000186A priority patent/KR101222736B1/ko
Priority to RSP-2010/0038A priority patent/RS51280B/sr
Priority to UY29002A priority patent/UY29002A1/es
Priority to ARP050102793A priority patent/AR049578A1/es
Priority to IL179906A priority patent/IL179906A/en
Priority to ZA200610698A priority patent/ZA200610698B/en
Priority to NO20070576A priority patent/NO20070576L/no
Priority to US12/629,630 priority patent/US7989620B2/en
Priority to CY20101100026T priority patent/CY1109728T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SE0401762A 2004-07-05 2004-07-05 Novel compounds SE0401762D0 (sv)

Priority Applications (33)

Application Number Priority Date Filing Date Title
SE0401762A SE0401762D0 (sv) 2004-07-05 2004-07-05 Novel compounds
UAA200613009A UA86977C2 (ru) 2004-07-05 2005-04-07 Производные гидантоина для лечения обструктивных болезней дыхательных путей
SA05260192A SA05260192B1 (ar) 2004-07-05 2005-06-29 مشتقات Hydantoin جديدة وعمليات لتحضيرها وتركيبات صيدلانية تحتوي عليها واستخداماتها
TW094121763A TWI353985B (en) 2004-07-05 2005-06-29 Novel compounds
MYPI20053029A MY145613A (en) 2004-07-05 2005-07-01 Novel compounds
RSP-2010/0038A RS51280B (sr) 2004-07-05 2005-07-04 Novi derivati hidantoina za tretman obstruktivnih bolesti dišnih puteva
ES05756403T ES2335424T3 (es) 2004-07-05 2005-07-04 Nuevos derivados de hidantoina para el tratamiento de enfermedades obstructivas de las vias respiratorias.
JP2007520267A JP4390833B2 (ja) 2004-07-05 2005-07-04 閉塞性気道疾患の処置のための新規ヒダントイン誘導体
DE602005017636T DE602005017636D1 (de) 2004-07-05 2005-07-04 Neue hydantoinderivate zur behandlung von obstruktiven atemwegserkrankungen
EP05756403A EP1778673B1 (en) 2004-07-05 2005-07-04 Novel hydantoin derivatives for the treatment of obstructive airway diseases
CNB2005800228017A CN100543024C (zh) 2004-07-05 2005-07-04 用于治疗阻塞性气道疾病的乙内酰脲衍生物
RU2007101236/04A RU2386629C2 (ru) 2004-07-05 2005-07-04 Новые гидантоиновые производные для лечения обструктивных заболеваний дыхательных путей
DK05756403.1T DK1778673T3 (da) 2004-07-05 2005-07-04 Nye hydantoin-derivater til behandling af obstruktive luftvejssygdomme
AT05756403T ATE448219T1 (de) 2004-07-05 2005-07-04 Neue hydantoinderivate zur behandlung von obstruktiven atemwegserkrankungen
PL05756403T PL1778673T3 (pl) 2004-07-05 2005-07-04 Nowe pochodne hydantoiny do leczenia obturacyjnych chorób dróg oddechowych
NZ552101A NZ552101A (en) 2004-07-05 2005-07-04 Novel hydantoin derivatives for the treatment of obstructive airway diseases
HR20100020T HRP20100020T1 (hr) 2004-07-05 2005-07-04 Novi derivati hidantoina za liječenje opstruktivnih bolesti dišnih putova
BRPI0512974-5A BRPI0512974A (pt) 2004-07-05 2005-07-04 novos derivados de hidantoìna para o tratamento de doenças obstrutivas das vias aéreas
CA2569716A CA2569716C (en) 2004-07-05 2005-07-04 Hydantoin derivatives for the treatment of obstructive airway diseases
MXPA06014661A MXPA06014661A (es) 2004-07-05 2005-07-04 Derivados de hidantoina novedosos para el tratamiento de enfermedades de las vias respiratorias obstructivas.
PCT/SE2005/001092 WO2006004532A1 (en) 2004-07-05 2005-07-04 Novel hydantoin derivatives for the treatment of obstructive airway diseases
PT05756403T PT1778673E (pt) 2004-07-05 2005-07-04 Novos derivados de hidantoína para o tratamento de doenças obstrutivas das vias respiratórias
AU2005260142A AU2005260142B2 (en) 2004-07-05 2005-07-04 Novel hydantoin derivatives for the treatment of obstructive airway diseases
SI200530892T SI1778673T1 (sl) 2004-07-05 2005-07-04 Novi hidantoinski derivati za zdravljenje obstrukcijskih bolezni dihalnih poti
HK07111163.1A HK1102814B (en) 2004-07-05 2005-07-04 Novel hydantoin derivatives for the treatment of obstructive airway diseases
KR1020077000186A KR101222736B1 (ko) 2004-07-05 2005-07-04 폐쇄성 기도 질환의 치료를 위한 신규 히단토인 유도체
ARP050102793A AR049578A1 (es) 2004-07-05 2005-07-05 Derivados de hidantoina, procesos de obtencion y composiciones farmaceuticas
UY29002A UY29002A1 (es) 2004-07-05 2005-07-05 Nuevos derivados de hidantoína, procesos parasu preparación, composiciones farmacéuticas que los contienen y su uso en terapia
IL179906A IL179906A (en) 2004-07-05 2006-12-07 Hydantoin derivatives, process for their preparation, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment of obstructive airway diseases
ZA200610698A ZA200610698B (en) 2004-07-05 2006-12-19 Novel hydantoin derivatives for the treatment of obstructive airway diseases
NO20070576A NO20070576L (no) 2004-07-05 2007-01-30 Nye hydantionderivater for behandling av obstruktive luftveissykdommer.
US12/629,630 US7989620B2 (en) 2004-07-05 2009-12-02 Hydantoin derivatives for the treatment of obstructive airway diseases
CY20101100026T CY1109728T1 (el) 2004-07-05 2010-01-11 Νεα παραγωγα υδαντοϊνης για τη θεραπεια αποφρακτικων νοσηματων της αναπνευστικης οδου

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0401762A SE0401762D0 (sv) 2004-07-05 2004-07-05 Novel compounds

Publications (1)

Publication Number Publication Date
SE0401762D0 true SE0401762D0 (sv) 2004-07-05

Family

ID=32768773

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0401762A SE0401762D0 (sv) 2004-07-05 2004-07-05 Novel compounds

Country Status (32)

Country Link
US (1) US7989620B2 (https=)
EP (1) EP1778673B1 (https=)
JP (1) JP4390833B2 (https=)
KR (1) KR101222736B1 (https=)
CN (1) CN100543024C (https=)
AR (1) AR049578A1 (https=)
AT (1) ATE448219T1 (https=)
AU (1) AU2005260142B2 (https=)
BR (1) BRPI0512974A (https=)
CA (1) CA2569716C (https=)
CY (1) CY1109728T1 (https=)
DE (1) DE602005017636D1 (https=)
DK (1) DK1778673T3 (https=)
ES (1) ES2335424T3 (https=)
HR (1) HRP20100020T1 (https=)
IL (1) IL179906A (https=)
MX (1) MXPA06014661A (https=)
MY (1) MY145613A (https=)
NO (1) NO20070576L (https=)
NZ (1) NZ552101A (https=)
PL (1) PL1778673T3 (https=)
PT (1) PT1778673E (https=)
RS (1) RS51280B (https=)
RU (1) RU2386629C2 (https=)
SA (1) SA05260192B1 (https=)
SE (1) SE0401762D0 (https=)
SI (1) SI1778673T1 (https=)
TW (1) TWI353985B (https=)
UA (1) UA86977C2 (https=)
UY (1) UY29002A1 (https=)
WO (1) WO2006004532A1 (https=)
ZA (1) ZA200610698B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
SE0401762D0 (sv) 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0401763D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Compounds
US7776869B2 (en) * 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
SE0403085D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
SE0403086D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
TW200740769A (en) 2006-03-16 2007-11-01 Astrazeneca Ab Novel process
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
WO2009007747A2 (en) * 2007-07-11 2009-01-15 Astrazeneca Ab Hydantoin derivatives used as mmp12 inhibitors
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
EP2907512A1 (en) 2014-02-14 2015-08-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Inhibitors of MMP-12 as antiviral Agents
RU2555341C1 (ru) * 2014-04-29 2015-07-10 Федеральное бюджетное учреждение науки "Федеральный научный центр медико-профилактических технологий управления рисками здоровью населения" (ФБУН "ФНЦ медико-профилактических технологий управления рисками здоровью населения") Способ профилактики развития у детей старше 5 лет неконтролируемых форм бронхиальной астмы, обусловленных воздействием марганца и ванадия
US10420341B2 (en) * 2015-01-30 2019-09-24 Basf Se Herbicidal phenylpyrimidines
US11180470B2 (en) 2016-07-25 2021-11-23 Basf Se Herbicidal pyrimidine compounds
CN109561685A (zh) 2016-07-25 2019-04-02 巴斯夫欧洲公司 除草的嘧啶化合物
AU2018283422A1 (en) 2017-06-14 2019-12-19 Basf Se Herbicidal pyrimidine compounds
WO2019121408A1 (en) 2017-12-20 2019-06-27 Basf Se Herbicidal pyrimidine compounds
IL279641B2 (en) 2018-07-16 2024-04-01 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN112955443A (zh) 2018-09-19 2021-06-11 拜耳公司 具有除草活性的取代的苯基嘧啶酰肼
US20230255943A1 (en) 2020-06-26 2023-08-17 The University Of Birmingham Mmp-9 and mmp-12 inhibition for treating spinal cord injury or related injury to neurological tissue
GB202403774D0 (en) 2024-03-15 2024-05-01 Univ Sheffield Treatment of stroke

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2327890A (en) * 1940-04-17 1943-08-24 Parke Davis & Co Substituted phenoxyalkyl ethers
US2745875A (en) * 1953-06-30 1956-05-15 Hoechst Ag Preparation of nu-acylamino-phenylpropane diols
US3452040A (en) * 1966-01-05 1969-06-24 American Home Prod 5,5-disubstituted hydantoins
US3529019A (en) * 1968-04-23 1970-09-15 Colgate Palmolive Co Alkylaryloxy alanines
US3849574A (en) * 1971-05-24 1974-11-19 Colgate Palmolive Co Alpha-substituted-beta-arylthioalkyl amino-acids,for increasing heart rate
US4315031A (en) * 1977-09-01 1982-02-09 Science Union Et Cie Thiosubstituted amino acids
GB1601310A (en) * 1978-05-23 1981-10-28 Lilly Industries Ltd Aryl hydantoins
JPS6172762A (ja) 1984-09-17 1986-04-14 Kanegafuchi Chem Ind Co Ltd 光学活性ヒダントイン類の製造法
JPS61212292A (ja) * 1985-03-19 1986-09-20 Mitsui Toatsu Chem Inc Ｄ−α−アミノ酸の製造方法
CA1325222C (en) 1985-08-23 1993-12-14 Lederle (Japan), Ltd. Process for producing 4-biphenylylacetic acid
GB8618559D0 (en) 1986-07-30 1986-09-10 Genetics Int Inc Rhodococcus bacterium
US4983771A (en) * 1989-09-18 1991-01-08 Hexcel Corporation Method for resolution of D,L-alpha-phenethylamine with D(-)mandelic acid
NL9000386A (nl) 1990-02-16 1991-09-16 Stamicarbon Werkwijze voor de bereiding van optisch aktief aminozuuramide.
DK161690D0 (da) 1990-07-05 1990-07-05 Novo Nordisk As Fremgangsmaade til fremstilling af enantiomere forbindelser
IL99957A0 (en) 1990-11-13 1992-08-18 Merck & Co Inc Piperidinylcamphorsulfonyl oxytocin antagonists and pharmaceutical compositions containing them
PH31245A (en) * 1991-10-30 1998-06-18 Janssen Pharmaceutica Nv 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.
US5308853A (en) * 1991-12-20 1994-05-03 Warner-Lambert Company Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
NL9201230A (nl) 1992-07-09 1994-02-01 Dsm Nv Werkwijze voor de bereiding van optisch aktief methionineamide.
EP0640594A1 (en) 1993-08-23 1995-03-01 Fujirebio Inc. Hydantoin derivative as metalloprotease inhibitor
WO1995014025A1 (en) 1993-11-16 1995-05-26 Merck & Co., Inc. Piperidinylcamphorsulfonyl oxytocin antagonists
DE69534213T2 (de) 1994-10-25 2006-01-12 Astrazeneca Ab Therapeutisch wirksame Heterocyclen
ZA96211B (en) 1995-01-12 1996-07-26 Teva Pharma Compositions containing and methods of using 1- aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US6166041A (en) * 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
IL123431A (en) * 1995-11-22 2001-05-20 Darwin Discovery Ltd Mercaptoalkyl peptidil compounds with imidazole transducer and their use as metallic protonase matrix (MMP) compounds and / or tumor cause factor (TNF)
GB9616643D0 (en) * 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
US5919790A (en) * 1996-10-11 1999-07-06 Warner-Lambert Company Hydroxamate inhibitors of interleukin-1β converting enzyme
WO1998017645A1 (en) * 1996-10-22 1998-04-30 Pharmacia & Upjohn Company α-AMINO SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS
WO1998050359A1 (en) 1997-05-06 1998-11-12 Novo Nordisk A/S Novel heterocyclic compounds
PT877019E (pt) * 1997-05-09 2002-05-31 Hoechst Ag Acidos diaminocarboxilicos substituidos
PL337854A1 (en) 1997-07-31 2000-09-11 Abbott Lab Inverse hydroxamines as inhibitors of intercellular substance metaloproteinases
TW514634B (en) 1997-10-14 2002-12-21 Lilly Co Eli Process to make chiral compounds
BR9814147A (pt) 1997-11-12 2000-10-03 Darwin Discovery Ltd "derivados de ácido carboxìlico e hidroxâmico tendo atividade inibitória de mmp e tnf"
JP4750272B2 (ja) 1998-02-04 2011-08-17 ノバルティス アーゲー マトリックス分解メタロプロテイナーゼを阻害するスルホニルアミノ誘導体
US6329418B1 (en) * 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
AU4074799A (en) 1998-05-14 1999-11-29 Du Pont Pharmaceuticals Company Substituted aryl hydroxamic acids as metalloproteinase inhibitors
IL140040A0 (en) 1998-06-03 2002-02-10 Guilford Pharm Inc N-linked sulfonamides of n-heterocyclic carboxylic acids or carboxylic acid isosteres
CA2333554A1 (en) * 1998-06-17 1999-12-23 Chu-Baio Xue Cyclic hydroxamic acids as metalloproteinase inhibitors
FR2782082B3 (fr) * 1998-08-05 2000-09-22 Sanofi Sa Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose
US6339101B1 (en) * 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
DE69907238T2 (de) 1998-10-07 2003-11-06 Yazaki Corp., Tokio/Tokyo Sol-gel verfahren unter verwendung poröser formen
EP1004578B1 (en) * 1998-11-05 2004-02-25 Pfizer Products Inc. 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
US6340691B1 (en) * 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
CN1343219A (zh) 1999-01-28 2002-04-03 中外制药株式会社 取代的苯乙基胺衍生物
US20020006920A1 (en) * 1999-07-22 2002-01-17 Robinson Ralph Pelton Arylsulfonylamino hydroxamic acid derivatives
ES2258431T3 (es) * 1999-08-02 2006-09-01 F. Hoffmann-La Roche Ag Proceso para la preparacion de derivados de benzotiofeno.
WO2001012189A1 (en) * 1999-08-12 2001-02-22 Pharmacia Italia S.P.A. 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
US6283379B1 (en) * 2000-02-14 2001-09-04 Kic Thermal Profiling Method for correlating processor and part temperatures using an air temperature sensor for a conveyorized thermal processor
WO2001062742A1 (en) * 2000-02-21 2001-08-30 Astrazeneca Ab Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
US6525202B2 (en) * 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US20020065219A1 (en) * 2000-08-15 2002-05-30 Naidu B. Narasimhulu Water soluble thiazolyl peptide derivatives
US20020091107A1 (en) * 2000-09-08 2002-07-11 Madar David J. Oxazolidinone antibacterial agents
EP1191024A1 (en) 2000-09-22 2002-03-27 Harald Tschesche Thiadiazines and their use as inhibitors of metalloproteinases
KR20030082990A (ko) * 2001-03-15 2003-10-23 아스트라제네카 아베 메탈로프로테이나제 억제제
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
CA2447475A1 (en) * 2001-05-25 2002-12-05 Chu-Biao Xue Hydantion derivatives as inhibitors of matrix metalloproteinases
GB0114004D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
SE0103710D0 (sv) * 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
CA2486350A1 (en) 2002-06-05 2003-12-24 Kaneka Corporation Process for producing optically active .alpha.-methylcysteine derivative
SE0202539D0 (sv) * 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
GB0221250D0 (en) 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
US20040266832A1 (en) * 2003-06-26 2004-12-30 Li Zheng J. Crystal forms of 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfonyl pyridine
TWI220073B (en) * 2003-07-24 2004-08-01 Au Optronics Corp Method for manufacturing polysilicon film
SE0401762D0 (sv) 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
SE0401763D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Compounds
US7648992B2 (en) * 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
TW200740769A (en) * 2006-03-16 2007-11-01 Astrazeneca Ab Novel process
TW200800954A (en) 2006-03-16 2008-01-01 Astrazeneca Ab Novel crystal modifications
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
MXPA06014661A (es) 2007-02-12
JP2008505171A (ja) 2008-02-21
RS51280B (sr) 2010-12-31
NO20070576L (no) 2007-04-10
HK1102814A1 (en) 2007-12-07
EP1778673A1 (en) 2007-05-02
IL179906A (en) 2011-11-30
CN1980914A (zh) 2007-06-13
PT1778673E (pt) 2010-01-13
NZ552101A (en) 2010-11-26
TWI353985B (en) 2011-12-11
RU2007101236A (ru) 2008-08-10
ES2335424T3 (es) 2010-03-26
AR049578A1 (es) 2006-08-16
CA2569716A1 (en) 2006-01-12
KR101222736B1 (ko) 2013-01-15
CN100543024C (zh) 2009-09-23
MY145613A (en) 2012-03-15
DE602005017636D1 (de) 2009-12-24
BRPI0512974A (pt) 2008-04-22
PL1778673T3 (pl) 2010-03-31
IL179906A0 (en) 2007-05-15
KR20070041495A (ko) 2007-04-18
AU2005260142A1 (en) 2006-01-12
JP4390833B2 (ja) 2009-12-24
CY1109728T1 (el) 2014-09-10
SI1778673T1 (sl) 2010-02-26
US20100144771A1 (en) 2010-06-10
SA05260192B1 (ar) 2009-02-07
DK1778673T3 (da) 2010-03-01
WO2006004532A1 (en) 2006-01-12
TW200616995A (en) 2006-06-01
EP1778673B1 (en) 2009-11-11
RU2386629C2 (ru) 2010-04-20
AU2005260142B2 (en) 2008-08-28
ATE448219T1 (de) 2009-11-15
US7989620B2 (en) 2011-08-02
HRP20100020T1 (hr) 2010-02-28
UA86977C2 (ru) 2009-06-10
UY29002A1 (es) 2006-02-24
ZA200610698B (en) 2008-06-25
CA2569716C (en) 2013-02-19

Similar Documents

Publication Publication Date Title
SE0401762D0 (sv) Novel compounds
TW200801003A (en) Novel compounds
SE0200920D0 (sv) Novel compounds
SE0302811D0 (sv) Novel compounds
TW200800999A (en) Novel compounds
SE0202539D0 (sv) Compounds
SE0301700D0 (sv) Novel compounds
TW200745084A (en) Novel compounds
SE0104140D0 (sv) Novel Compounds
TW200745114A (en) Novel compounds
ATE433447T1 (de) Pyrimiidinverbindungen
SE0202133D0 (sv) Novel compounds
TW200621777A (en) New dihydropteridione derivatives, process for their manufacture and their use as medicament
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
TW200833670A (en) Novel compounds 569
TW200613243A (en) Novel compounds
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
SE0300480D0 (sv) Novel compounds
TW200621262A (en) New dihydropteridione derivatives, process for their manufacture and their use as medicament
DE602004024213D1 (en) Aminopropanolderivate
TW200738659A (en) Novel compounds
SE0302139D0 (sv) Novel compounds
SE0303541D0 (sv) New compounds
MX2009006010A (es) Derivados de amina y su uso en enfermedades mediadas por el adrenoreceptor beta 2.
SE0400850D0 (sv) Novel Compounds